|
1
|
Agarwal G, Nanda G, Lal P, Mishra A,
Agarwal A, Agrawal V and Krishnani N: Outcomes of triple-negative
breast cancers (TNBC) compared with non-TNBC: Does the survival
vary for all stages? World J Surg. 40:1362–1372. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lehmann BD, Bauer JA, Chen X, Sanders ME,
Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human
triple-negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest. 121:2750–2767.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kumar P and Aggarwal R: An overview of
triple-negative breast cancer. Arch Gynecol Obstet. 293:247–269.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Palma G, Frasci G, Chirico A, Esposito E,
Siani C, Saturnino C, Arra C, Ciliberto G, Giordano A and D'Aiuto
M: Triple negative breast cancer: Looking for the missing link
between biology and treatments. Oncotarget. 6:26560–26574. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yadav BS, Chanana P and Jhamb S:
Biomarkers in triple negative breast cancer: A review. World J Clin
Oncol. 6:252–263. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Merrouche Y, Fabre J, Cure H, Garbar C,
Fuselier C, Bastid J, Antonicelli F, Al-Daccak R, Bensussan A and
Giustiniani J: IL-17E synergizes with EGF and confers in vitro
resistance to EGFR-targeted therapies in TNBC cells. Oncotarget.
7:53350–53361. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Von Minckwitz G and Martin M: Neoadjuvant
treatments for triple-negative breast cancer (TNBC). Ann Oncol. 23
Suppl 6:vi35–vi39. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Siddik ZH: Cisplatin: Mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen Y, Gao Y, Zhang K, Li C, Pan Y, Chen
J, Wang R and Chen L: MicroRNAs as regulators of cisplatin
resistance in lung cancer. Cell Physiol Biochem. 37:1869–1880.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bartholin L, Powers SE, Melhuish TA, Lasse
S, Weinstein M and Wotton D: TGIF inhibits retinoid signaling. Mol
Cell Biol. 26:990–1001. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ferrand N, Demange C, Prunier C, Seo SR
and Atfi A: A mechanism for mutational inactivation of the
homeodomain protein TGIF in holoprosencephaly. FASEB J. 21:488–496.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hu Y, Yu H, Shaw G, Renfree MB and Pask
AJ: Differential roles of TGIF family genes in mammalian
reproduction. BMC Dev Biol. 11:582011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Massagué J: TGFbeta in cancer. Cell.
134:215–230. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sharma M and Sun Z: 5′TG3′ interacting
factor interacts with Sin3A and represses AR-mediated
transcription. Mol Endocrinol. 15:1918–1928. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wotton D, Lo RS, Lee S and Massagué J: A
smad transcriptional corepressor. Cell. 97:29–39. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zerlanko BJ, Bartholin L, Melhuish TA and
Wotton D: Premature senescence and increased TGFβ signaling in the
absence of Tgif1. PLoS One. 7:e354602012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gripp KW, Wotton D, Edwards MC, Roessler
E, Ades L, Meinecke P, Richieri-Costa A, Zackai EH, Massagué J,
Muenke M and Elledge SJ: Mutations in TGIF cause holoprosencephaly
and link NODAL signalling to human neural axis determination. Nat
Genet. 25:205–208. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang Y, Wang H, Gao H, Xu B, Zhai W, Li J
and Zhang C: Elevated expression of TGIF is involved in lung
carcinogenesis. Tumour Biol. 36:9223–9231. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Y, Pan T, Wang H, Li L, Li J, Zhang C
and Yang H: Silencing of TGIF attenuates the tumorigenicity of A549
cells in vitro and in vivo. Tumour Biol. 37:12725–12730. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xiang G, Yi Y, Weiwei H and Weiming W:
TGIF1 promoted the growth and migration of cancer cells in nonsmall
cell lung cancer. Tumour Biol. 36:9303–9310. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Borlak J, Meier T, Halter R, Spanel R and
Spanel-Borowski K: Epidermal growth factor-induced hepatocellular
carcinoma: Gene expression profiles in precursor lesions, early
stage and solitary tumours. Oncogene. 24:1809–1819. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu ZM, Tseng HY, Tsai HW, Su FC and Huang
HS: Transforming growth factor β-interacting factor-induced
malignant progression of hepatocellular carcinoma cells depends on
superoxide production from Nox4. Free Radic Biol Med. 84:54–64.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Imoto I, Pimkhaokham A, Watanabe T,
Saito-Ohara F, Soeda E and Inazawa J: Amplification and
overexpression of TGIF2, a novel homeobox gene of the TALE
superclass, in ovarian cancer cell lines. Biochem Biophys Res
Commun. 276:264–270. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hamid R and Brandt SJ: Transforming
growth-interacting factor (TGIF) regulates proliferation and
differentiation of human myeloid leukemia cells. Mol Oncol.
3:451–463. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hu ZL, Wen JF, Xiao DS, Zhen H and Fu CY:
Effects of transforming growth interacting factor on biological
behaviors of gastric carcinoma cells. World J Gastroenterol.
11:84–88. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yeh BW, Wu WJ, Li WM, Li CC, Huang CN,
Kang WY, Liu ZM and Huang HS: Overexpression of TG-interacting
factor is associated with worse prognosis in upper urinary tract
urothelial carcinoma. Am J Pathol. 181:1044–1055. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nakakuki K, Imoto I, Pimkhaokham A, Fukuda
Y, Shimada Y, Imamura M, Amagasa T and Inazawa J: Novel targets for
the 18p11.3 amplification frequently observed in esophageal
squamous cell carcinomas. Carcinogenesis. 23:19–24. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang MZ, Ferrigno O, Wang Z, Ohnishi M,
Prunier C, Levy L, Razzaque M, Horne WC, Romero D, Tzivion G, et
al: TGIF governs a feed-forward network that empowers Wnt signaling
to drive mammary tumorigenesis. Cancer Cell. 27:547–560. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Razzaque MS and Atfi A: TGIF function in
oncogenic Wnt signaling. Biochim Biophys Acta. 1865:101–104.
2016.PubMed/NCBI
|
|
31
|
Kwon YJ, Leibovitch BA, Bansal N, Pereira
L, Chung CY, Ariztia EV, Zelent A, Farias EF and Waxman S: Targeted
interference of SIN3A-TGIF1 function by SID decoy treatment
inhibits Wnt signaling and invasion in triple negative breast
cancer cells. Oncotarget. 8:88421–88436. 2016.PubMed/NCBI
|
|
32
|
Huang HS, Liu ZM and Hong DY: Blockage of
JNK pathway enhances arsenic trioxide-induced apoptosis in human
keratinocytes. Toxicol Appl Pharmacol. 244:234–241. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu ZM, Tseng JT, Hong DY and Huang HS:
Suppression of TG-interacting factor sensitizes arsenic
trioxide-induced apoptosis in human hepatocellular carcinoma cells.
Biochem J. 438:349–358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yeh BW, Li WM, Li CC, Kang WY, Huang CN,
Hour TC, Liu ZM, Wu WJ and Huang HS: Histone deacetylase inhibitor
trichostatin A resensitizes gemcitabine resistant urothelial
carcinoma cells via suppression of TG-interacting factor. Toxicol
Appl Pharmacol. 290:98–106. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tsimberidou AM, Braiteh F, Stewart DJ and
Kurzrock R: Ultimate fate of oncology drugs approved by the us food
and drug administration without a randomized Trial. J Clin Oncol.
27:6243–6250. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gonzalez VM, Fuertes MA, Alonso C and
Perez JM: Is cisplatin-induced cell death always produced by
apoptosis? Mol Pharmacol. 59:657–663. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cepeda V, Fuertes MA, Castilla J, Alonso
C, Quevedo C and Pérez JM: Biochemical mechanisms of cisplatin
cytotoxicity. Anticancer Agents Med Chem. 7:3–18. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Galluzzi L, Senovilla L, Vitale I, Michels
J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms
of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhou FF, Yan M, Guo GF, Wang F, Qiu HJ,
Zheng FM, Zhang Y, Liu Q, Zhu XF and Xia LP: Knockdown of eIF4E
suppresses cell growth and migration, enhances chemosensitivity and
correlates with increase in Bax/Bcl-2 ratio in triple-negative
breast cancer cells. Med Oncol. 28:1302–1307. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yang J, Wu Y, Wang X, Xu L, Zhao X and
Yang Y: Chemoresistance is associated with overexpression of HAX-1,
inhibition of which resensitizes drug-resistant breast cancer cells
to chemotherapy. Tumour Biol. 39:10104283176922282017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hong Y, Yang J, Wu W, Wang W, Kong X, Wang
Y, Yun X, Zong H, Wei Y, Zhang S and Gu J: Knockdown of BCL2L12
leads to cisplatin resistance in MDA-MB-231 breast cancer cells.
Biochim Biophys Acta. 1782:649–657. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang R, Li Y, Dong X, Peng L and Nie X:
MiR-363 sensitizes cisplatin-induced apoptosis targeting in Mcl-1
in breast cancer. Med Oncol. 31:3472014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wu X, Li L, Li Y and Liu Z: MiR-153
promotes breast cancer cell apoptosis by targeting HECTD3. Am J
Cancer Res. 6:1563–1571. 2016.PubMed/NCBI
|
|
44
|
Porter AG and Jänicke RU: Emerging roles
of caspase-3 in apoptosis. Cell Death Differ. 6:99–104. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Del Bello B, Valentini MA, Mangiavacchi P,
Comporti M and Maellaro E: Role of caspases-3 and −7 in Apaf-1
proteolytic cleavage and degradation events during
cisplatin-induced apoptosis in melanoma cells. Exp Cell Res.
293:302–310. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Soldani C and Scovassi AI:
Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: An update.
Apoptosis. 7:321–328. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Michels J, Vitale I, Galluzzi L, Adam J,
Olaussen KA, Kepp O, Senovilla L, Talhaoui I, Guegan J, Enot DP, et
al: Cisplatin resistance associated with PARP hyperactivation.
Cancer Res. 73:2271–2280. 2013. View Article : Google Scholar : PubMed/NCBI
|
